OakChart

Ceribell Inc

CBLLHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 12:33 PM ET

27.76+0.28 (1.02%)
2026-11-11 18:34 CET
Market cap
1,067.19 USD m
Revenue, TTM
108.72 USD m
Net income, TTM
-73.88 USD m
Free cash flow, TTM
-56.43 USD m
EPS diluted, TTM
-1.95
P/E
-
Compare

Price

CBLL against its 20, 50 and 200-day averages
2050200miss
20.0025.00928K1.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CBLLclose 27.7620-day 27.1050-day 25.46200-day 20.9827.7652w high

3.9% under the 52-week high of 28.89 on 3 Nov 2026. 52-week low 11.75 on 11 Nov 2025. Last 15 sessions, 32.2% high to low

Profile

CBLL
52-week range, 93% of the way up
11.7528.89

Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.

IndexRUT
Employees327
IPOOct 11, 2024
Beta0.84
ATR, 14d1.57
Rel volume0.33
Short float7.56%
Insider own33.38%
Inst own64.59%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.08B
Enterprise Value982.24M
Income-73.88M
Sales108.72M
Book/sh3.03
Cash/sh3.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees327
IPOOct 11, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S9.92
P/B9.17
P/C9.18
P/FCF-
EV/EBITDA-
EV/Sales9.03
Quick Ratio7.67
Current Ratio8.05
Debt/Eq0.18
LT Debt/Eq0.17
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.95
EPS next Y-1.76
EPS next Q-0.50
EPS this Y-42.14%
EPS next Y15.42%
EPS next 5Y0.15%
EPS past 3/5Y-10.19% -
Sales past 3/5Y50.90% -
EPS Y/Y TTM-34.52%
Sales Y/Y TTM31.28%
EPS Q/Q-51.61%
Sales Q/Q29.89%
EarningsNov 03 AMC
EPS/Sales Surpr.-7.84% 0.56%

Ownership

Insider Own33.38%
Insider Trans-3.93%
Inst Own64.59%
Inst Trans3.48%
ROA-41.52%
ROE-52.47%
ROIC-53.55%
Gross Margin89.26%
Oper. Margin-69.79%
Profit Margin-67.96%
SMA202.44%
SMA509.03%
SMA20032.30%
Trades-

Technical

Shs Outstand38.82M
Shs Float25.87M
Short Float7.56%
Short Ratio4.15
Short Interest1.96M
52W High28.89 -3.91%
52W Low11.75 136.26%
Volatility10.57% 6.87%
ATR (14)1.57
RSI (14)57.08
Beta0.84
Rel Volume0.33
Avg Volume471.19K
Volume76,669

Performance

Perf Week1.35%
Perf Month6.20%
Perf Quarter19.40%
Perf Half Y55.00%
Perf YTD26.58%
Perf Year121.73%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price31.57
Prev Close27.48
Price27.76
Change %1.02%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Oct 21, 2025InitiatedRRaymond JamesStrong Buy$19-31.6%
Jun 24, 2025InitiatedBBTIG ResearchBuy$30+8.1%
Apr 04, 2025InitiatedLLadenburg ThalmannBuy$32+15.3%
Nov 05, 2024InitiatedWWilliam BlairOutperform
Nov 05, 2024InitiatedTTD CowenBuy$31+11.7%
Nov 05, 2024InitiatedJJP MorganOverweight$32+15.3%
Nov 05, 2024InitiatedCCanaccord GenuityBuy$30+8.1%
Nov 05, 2024InitiatedBBofA SecuritiesBuy$32+15.3%

Peers

Mkt cap
TickerCompanyMkt cap
NPCENeuroPace Inc440.03M
NMTCNeuroOne Medical Technologies Corp6.93M
IRTCiRhythm Holdings Inc2.96B
BFLYButterfly Network Inc1.85B
LIVNLivaNova PLC4.99B
PHGKoninklijke Philips NV ADR29.42B
BWAYBrainsway Ltd ADR443.57M
MDTMedtronic Plc129.11B
ECORElectroCore Inc73.62M
AIFFFirefly Neuroscience Inc16.24M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Taylor Joseph MichaelDirectorNov 09 '26Sale27.2210,200277,64438,278Nov 10 04:26 PM
Taylor Joseph MichaelDirectorNov 09 '26Proposed Sale26.7510,200272,850Nov 09 10:23 AM
Woo RaymondChief Technology OfficerNov 02 '26Option Exercise3.654,88717,862208,005Nov 04 12:22 PM
Woo RaymondChief Technology OfficerNov 02 '26Sale26.964,887131,754203,118Nov 04 12:22 PM
Woo RaymondOfficerNov 02 '26Proposed Sale26.964,887131,754Nov 02 11:13 AM
Woo RaymondChief Technology OfficerOct 01 '26Option Exercise3.654,88717,862208,005Oct 02 05:19 PM
Woo RaymondChief Technology OfficerOct 01 '26Sale24.384,887119,145203,118Oct 02 05:19 PM
Woo RaymondOfficerOct 01 '26Proposed Sale24.384,887119,145Oct 01 10:45 AM
Chao XingjuanPresident and CEOSep 15 '26Sale25.0320,846521,775746,345Sep 17 08:45 PM
Blumberg ScottChief Financial OfficerSep 15 '26Option Exercise9.418467,961147,446Sep 17 08:40 PM
Blumberg ScottChief Financial OfficerSep 15 '26Sale25.0084621,150146,600Sep 17 08:40 PM
Blumberg ScottOfficerSep 15 '26Proposed Sale25.0084621,151Sep 15 04:36 PM
Chao XingjuanOfficerSep 15 '26Proposed Sale25.0320,846521,773Sep 15 04:29 PM
Foehr DavidSenior VP, Finance and PAOSep 08 '26Option Exercise4.707,50035,25041,644Sep 10 08:27 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
FFSMFidelity Fundamental Small-Mid Cap ETFAUM: 1.55B
LFSCF/m Emerald Life Sciences Innovation ETFAUM: 130.02M
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 190
  • Ceribell Edges Estimates And Nudges Guidance Higher, But Slowing Growth And Wider Losses Test A Stock Priced Near Its Highs (Earnings Whispers)
  • Ceribell Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution (GlobeNewswire)
  • Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
  • Ceribell Heads Into Q3 With Street Forecasts Still Below Its Raised Revenue Guidance (Earnings Whispers)
  • Loading…
  • Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire) +6.46%
  • Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis (GlobeNewswire)
  • CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ... (GuruFocus.com) +10.41%
  • Ceribell Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review (GlobeNewswire)
  • What To Expect From CeriBell Inc (CBLL) Q2 2026 Earnings (GuruFocus.com)
  • CeriBell Inc (CBLL) Q2 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
  • CeriBell Shares Gain After Medicare Approves Additional Payment for Delirium Monitoring System (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.550-0.510-0.55029.3429.188
2026Q22026-08-10-0.510-0.471-0.50728.1027.288
2026Q12026-05-11-0.520-0.391-0.52426.4926.098
2025Q42026-02-24-0.360-0.412-0.36324.7823.938
2025Q32025-11-04-0.370-0.414-0.36622.5921.778
2025Q22025-08-05-0.380-0.397-0.37621.2020.457
2025Q12025-05-08-0.360-0.407-0.35620.4919.266
2024Q42025-02-25-0.400-0.318-0.35118.5317.555
2024Q32024-11-12-1.850-0.343-0.29117.2016.934
2024Q22024-08-28-0.309--0.30015.23--
2026Q4---0.498--31.898
2027Q1---0.455--34.276
2027Q2---0.458--35.996
2027Q3---0.452--37.346
2027Q4---0.412--40.595
2028Q1---0.369--43.534

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-3.390-2.198-1.12865.4464.28
2025FY-1.460-1.507-1.45389.0688.19
2026FY--2.075--115.83
2027FY--1.755--147.71
2028FY--1.453--187.12
2029FY--1.150--230.6
2030FY--1.110--281.7

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0482031.8931.1032.20
2026Q4S2026-11-0380031.7030.9031.97
2026Q4S2026-11-0280031.7030.9031.97
2026Q4S2026-10-2580031.7230.9032.00
2026Q4S2026-10-1383031.7230.9032.00
2026Q4S2026-10-0983031.7230.9032.00
2026Q4S2026-09-1883031.7330.9032.00
2026Q4S2026-09-1783031.7230.9032.00
2026Q4S2026-09-1083031.7330.9032.00
2026Q4S2026-09-0883031.7230.9032.00
2026Q4S2026-08-1783031.7330.9032.00
2026Q4S2026-08-1383031.7230.9032.00
2026Q4S2026-08-1183031.7330.9032.00
2026Q4S2026-07-2680031.4230.7032.00

Estimate history

EPS, annual-1.093-0.866-1.128-1.462-1.9487
Period2022202320242025TTM
EPS, quarterly-0.291-0.351-0.356-0.376-0.366-0.363-0.524-0.507-0.555
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.92245.22565.44489.063108.72
Period2022202320242025TTM
Sales, quarterly17.19518.53420.49121.19922.58924.78426.49428.09729.341
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.01934.01935.85137.48538.821
Period2022202320242025MRQ
Shares, quarterly35.82435.85135.89736.637.04837.48537.8638.22338.821
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue108.7289.0665.4445.2325.92
Cost of Goods Sold Incl. D&A11.6710.798.697.064.43
Gross Profit97.0478.2756.7538.1621.49
Selling, General and Administrative Excl. Other172.91136.6896.4668.2057.51
Research and Development25.3719.1413.568.997.24
Other Operating Expense0.000.000.000.000.00
Operating Income-75.87-58.40-39.71-30.04-36.02
Interest Expense1.601.891.992.101.60
Unusual Expense1.550.001.50-0.050.17
Net Income Before Taxes-73.88-53.41-40.45-29.45-37.16
Income Taxes0.000.000.000.010.00
Consolidated Net Income-73.88-53.41-40.45-29.46-37.16
Net Income From Continuing Operations-73.88-53.41-40.45-29.46-37.16
Net Income-73.88-53.41-40.45-29.46-37.16
EPS (Recurring)-1.89-1.46-1.10-0.87-1.09
EPS (Basic, Before Extraordinaries)-1.95-1.46-1.13-0.87-1.09
EPS (Diluted)-1.95-1.46-1.13-0.87-1.09
EBITDA-74.85-57.06-38.57-29.19-35.52
Non-Operating Income (Expense)5.146.882.742.640.64
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense21.0812.225.412.126.26
Price To Sales Ratio8.649.0014.18--
Gross Margin89.2687.8986.7284.3882.91
Operating Margin-69.79-65.57-60.68-66.43-138.96
Net Margin-67.96-59.97-61.82-65.15-143.37
Shares Outstanding38.8237.4935.8534.0234.02
Market Capitalization1,067.191,067.19927.13926.41-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue29.3428.1026.4924.7822.5921.2020.4918.53
Cost of Goods Sold Incl. D&A3.002.163.373.142.652.522.482.30
Gross Profit26.3425.9423.1221.6419.9418.6818.0116.24
Selling, General and Administrative Excl. Other46.8945.9243.8736.2434.5933.6332.2129.12
Research and Development7.406.756.165.064.984.854.253.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.55-19.98-20.75-14.60-14.65-14.95-14.21-12.88
Interest Expense0.270.440.430.460.480.480.470.50
Unusual Expense1.550.000.000.000.000.000.001.08
Net Income Before Taxes-21.35-19.27-19.74-13.53-13.46-13.64-12.78-12.58
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-21.35-19.27-19.74-13.53-13.46-13.64-12.78-12.58
Net Income From Continuing Operations-21.35-19.27-19.74-13.53-13.46-13.64-12.78-12.58
Net Income-21.35-19.27-19.74-13.53-13.46-13.64-12.78-12.58
EPS (Recurring)-0.53-0.51-0.52-0.36-0.37-0.38-0.36-0.33
EPS (Basic, Before Extraordinaries)-0.55-0.51-0.52-0.36-0.37-0.38-0.36-0.35
EPS (Diluted)-0.55-0.51-0.52-0.36-0.37-0.38-0.36-0.35
EBITDA-20.30-19.74-20.51-14.30-14.26-14.63-13.87-12.52
Non-Operating Income (Expense)1.011.151.441.531.661.791.901.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.106.003.724.263.153.171.852.20
Price To Sales Ratio8.647.257.269.165.118.78--
Gross Margin89.7792.3287.2787.3388.2888.1387.8887.61
Operating Margin-70.03-71.11-78.30-58.89-64.84-70.53-69.33-69.52
Net Margin-72.77-68.58-74.50-54.58-59.61-64.36-62.35-67.85
Shares Outstanding38.8238.2237.8637.4937.0536.6035.9035.85
Market Capitalization1,067.19737.99689.96813.51421.27676.96689.03927.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments159.26194.3734.4968.23
Short Term Receivables15.0510.887.965.29
Inventories7.296.945.874.08
Other Current Assets2.913.252.131.17
Total Current Assets184.51215.4450.4578.77
Net Property, Plant & Equipment4.334.453.743.87
Total Investments and Advances0.000.000.000.00
Intangible Assets0.810.470.480.49
Other Assets6.165.074.253.33
Total Assets195.80225.4158.9286.46
Short Term Debt Incl. Current Port. of LT Debt1.101.0912.533.13
Accounts Payable2.841.140.730.42
Other Current Liabilities15.2510.768.346.31
Total Current Liabilities19.1912.9921.609.86
Long Term Debt21.1720.871.6815.09
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.110.390.480.49
Total Liabilities40.4734.2523.7625.44
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00147.41147.41
Common Equity155.34191.16-112.25-86.40
Total Shareholders Equity155.34191.1635.1661.01
Accumulated Minority Interest0.000.000.000.00
Total Equity155.34191.1635.1661.01
Total Liabilities & Stockholders Equity195.80225.4158.9286.46
Book Value Per Share4.145.33-3.30-2.54
Tangible Book Value Per Share4.125.32-3.31-2.55
Full-Time Employees327281229-
Price to Book Ratio9.08-6.82-6.81-
Return on Assets-25.36-28.46-40.53-
Return on Equity-30.83-35.75-61.27-
Return on Invested Capital-30.26-19.08-79.98-48.83
Quick Ratio9.2416.052.067.57
Current Ratio9.6116.592.347.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-73.88-53.41-40.45-29.46-37.16
Depreciation1.021.341.140.850.50
Other Funds (Non Cash)19.9310.487.143.158.55
Funds from Operations-52.93-41.59-32.17-25.46-28.12
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-3.080.63-3.17-3.70-3.88
Cash from Operating Activities-56.01-40.96-35.35-29.16-32.00
Capital Expenditures-2.36-1.52-1.60-1.76-1.40
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments71.12-116.610.000.000.00
Purchase of Investments-110.38-210.810.000.000.00
Sale Or Maturity of Investments181.5094.200.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities68.77-118.14-1.60-1.76-1.40
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock7.685.44188.910.9349.84
Repurchase of Common Pref Stock0.000.000.000.00-0.31
Sale of Common Pref Stock7.685.44188.910.9350.15
Proceedsfrom Stock Options0.000.00187.790.0050.00
Issuance or Reduction of Debt, Net-1.950.000.00-3.75-0.04
Change in Long Term Debt-1.950.000.00-3.75-0.04
Issuance of Long Term Debt39.450.000.000.000.00
Reduction of Long Term Debt-41.400.000.00-3.75-0.04
Net Financing Active Other Cash Flow-0.24-0.247.910.000.00
Other Financing Activities Uses-0.24-0.240.000.000.00
Cash from Financing Activities5.505.20196.82-2.8249.80
Net Change in Cash18.25-153.89159.88-33.7416.40
Free Cash Flow-56.43-41.73-36.69-30.14-32.52
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments117.47129.26141.18159.26168.54177.43
Short Term Receivables17.7915.9915.7115.0512.2312.31
Inventories6.966.746.907.296.026.00
Other Current Assets2.993.662.882.912.862.02
Total Current Assets145.21155.65166.68184.51189.66197.76
Net Property, Plant & Equipment3.293.543.974.333.463.76
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.141.030.960.810.680.56
Other Assets6.736.126.476.165.725.61
Total Assets156.37166.35178.08195.80199.53207.69
Short Term Debt Incl. Current Port. of LT Debt1.221.181.141.101.181.15
Accounts Payable2.333.191.982.842.182.44
Other Current Liabilities14.4812.8413.0615.2511.8111.43
Total Current Liabilities18.0317.2016.1819.1915.1715.01
Long Term Debt20.4320.7320.9821.1720.1720.41
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.370.110.110.110.110.11
Total Liabilities38.8338.0337.2740.4735.4435.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity117.54128.31140.81155.34164.08172.16
Total Shareholders Equity117.54128.31140.81155.34164.08172.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity117.54128.31140.81155.34164.08172.16
Total Liabilities & Stockholders Equity156.37166.35178.08195.80199.53207.69
Book Value Per Share3.033.363.724.144.434.70
Tangible Book Value Per Share3.003.333.694.124.414.69
Full-Time Employees---327--
Price to Book Ratio9.085.234.424.952.443.72
Return on Assets-41.52-35.29-30.84-25.36-42.55-
Return on Equity-52.47-43.93-37.53-30.83-59.78-
Return on Invested Capital-15.48-12.93-12.20-7.66-7.31-7.08
Quick Ratio7.678.669.879.2412.1112.77
Current Ratio8.059.0510.309.6112.5013.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.35-19.27-19.74-13.53-13.46-13.64
Depreciation0.250.240.240.290.390.32
Other Funds (Non Cash)8.435.473.192.842.412.80
Funds from Operations-12.67-13.55-16.31-10.39-10.67-10.52
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.400.69-2.98-0.38-0.582.99
Cash from Operating Activities-13.08-12.86-19.30-10.77-11.25-7.53
Capital Expenditures-0.76-0.22-0.83-0.55-0.46-0.23
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments21.58-0.3823.2726.66-6.48-107.46
Purchase of Investments-12.72-48.88-26.73-22.04-45.98-113.46
Sale Or Maturity of Investments34.3048.5050.0048.7039.506.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities20.82-0.6122.4426.11-6.94-107.69
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.530.881.631.641.642.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.530.881.631.641.642.01
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-1.950.000.000.000.000.00
Change in Long Term Debt-1.950.000.000.000.000.00
Issuance of Long Term Debt39.450.000.000.000.000.00
Reduction of Long Term Debt-41.400.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.240.000.00
Other Financing Activities Uses0.000.000.00-0.240.000.00
Cash from Financing Activities1.580.881.631.401.792.01
Net Change in Cash9.33-12.594.7816.74-16.40-113.22
Free Cash Flow-13.18-12.88-19.42-10.95-11.62-7.60

Revenue breakdown

Product2024: 50.08M 2025: 67.34M
Subscription2024: 15.37M 2025: 21.73M
United States2024: 65.44M 2025: 89.06M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.56%2.0M25.9M431.01K
2026-10-158.43%2.2M25.6M398.70K
2026-09-307.89%2.0M25.6M379.99K
2026-09-157.11%1.8M25.6M387.41K
2026-08-317.46%1.9M25.6M384.12K
2026-08-148.28%2.1M25.4M373.82K
2026-07-318.17%2.0M24.7M357.54K
2026-07-157.47%1.8M24.7M332.89K
2026-06-307.99%2.0M24.7M320.18K
2026-06-158.21%2.0M24.5M291.13K
2026-05-297.86%1.9M24.5M296.22K
2026-05-157.99%2.0M24.6M308.42K
2026-04-307.74%1.9M24.4M291.23K
2026-04-156.28%1.5M24.4M308.89K
2026-03-317.82%1.9M24.0M335.37K
2026-03-136.90%1.7M24.0M372.63K
2026-02-278.01%1.9M24.0M430.44K
2026-02-136.90%1.7M24.0M457.47K
2026-01-307.26%1.6M22.4M461.45K
2026-01-157.16%1.6M22.4M457.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5013.3017.400.006.4050.000.000.902-0.2710.008
call15.0010.8014.900.005.2620.000.000.876-0.2630.009
call17.508.3012.400.004.2720.000.000.846-0.2500.010
call20.005.809.900.003.4670.000.000.809-0.2330.012
call22.503.507.400.002.7490.000.000.759-0.2080.014
call25.001.004.902.602.01937.000.000.685-0.1890.015
call30.000.101.000.301.0611061.000.363-0.1030.016
call35.000.002.350.001.7030.000.000.251-0.1330.014
put12.500.002.150.056.4268.000.00-0.097-0.2660.008
put15.000.002.150.005.2740.000.00-0.123-0.2590.009
put17.500.002.150.004.3380.000.00-0.154-0.2480.010
put20.000.002.150.303.5162.000.00-0.190-0.2310.012
put22.500.002.151.652.7432.000.00-0.242-0.2060.014
put25.000.002.350.732.1795.000.00-0.315-0.1860.015
put30.000.504.500.001.8230.000.00-0.633-0.1010.016
put35.005.509.200.002.4510.000.00-0.753-0.1330.014

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100409.40K2
2026-1000119.15K1
2026-09001.88M6
2026-08003.03M12
2026-0700776.10K1
2026-06004.93M4
2026-05001.24M8
2026-0400923.84K2
2026-0300924.06K4
2026-02001.74M12
2026-01002.67M5
2025-12003.74M10
2025-1100892.96K2

Institutional holders

Manager% owned
FMR LLC16.48%
TPG GP A, LLC9.91%
Red Tree Management, LLC5.75%
BlackRock, Inc.5.10%
VANGUARD CAPITAL MANAGEMENT LLC2.98%
KCM Capital Inc2.96%
FEDERATED HERMES, INC.2.48%
FRANKLIN RESOURCES INC2.42%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.37%
TimesSquare Capital Management, LLC2.04%

Funds

Fund% owned
Fidelity Small Cap Growth Fund4.32%
Fidelity Stock Selector Small Cap Fund2.64%
Federated Hermes Kaufmann Small Cap Fund2.48%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.24%
Fidelity Small Cap Growth K6 Fund2.19%
Franklin Small Cap Growth Fund1.98%
Fidelity Series Small Cap Opportunities Fund1.94%
iShares Russell 2000 ETF1.88%
Select Medical Technology and Devices Portfolio1.11%
BNY Mellon Small/Mid Cap Growth Fund1.03%

OakChart. CBLL. Cached 15 minutes.